Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

374 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Therapeutic strategy for advanced stages salivary carcinomas of the tongue: A multicenter REFCOR study.
Poissonnet V, Chabrillac E, Uro-Coste E, Woisard V, Moya-Plana A, Espitalier F, Castelli J, Dedieu T, Salas S, Garrel R, Baudouin R, Poissonnet G, Castain C, Barbut J, Mirghani H, Evrard D, Bouchain O, Marie JP, Orliac H, Ceruse P, Dufour X, Brenet E, Rambeau A, Herman P, Abu Shama Y, Bertolus C, Atallah S, Morinière S, Righini C, Mouawad F, Duflo S, Segier B, Vergez S. Poissonnet V, et al. Among authors: salas s. Oral Oncol. 2024 Dec;159:107072. doi: 10.1016/j.oraloncology.2024.107072. Epub 2024 Oct 20. Oral Oncol. 2024. PMID: 39432991 Free article.
Survival outcomes, prognostic factors, and effect of adjuvant radiotherapy and prophylactic neck dissection in salivary acinic cell carcinoma: A prospective multicenter REFCOR study of 187 patients.
Chatelet F, Ferrand FR, Atallah S, Thariat J, Mouawad F, Fakhry N, Malard O, Even C, de Monès E, Uro-Coste E, Benzerdjeb N, Hans S, Testelin S, Mauvais O, Evrard D, Bastit V, Salas S, Espitalier F, Classe M, Digue L, Doré M, Wong S, Dupin C, Nguyen F, Bettoni J, Lapierre A, Colin E, Philouze P, Vergez S, Baujat B, Herman P, Verillaud B; REFCOR members. Chatelet F, et al. Among authors: salas s. Eur J Cancer. 2023 May;185:11-27. doi: 10.1016/j.ejca.2023.02.020. Epub 2023 Mar 2. Eur J Cancer. 2023. PMID: 36947928
Characterization of a Molecularly Distinct Subset of Oncocytic Pleomorphic Adenomas/Myoepitheliomas Harboring Recurrent ZBTB47-AS1::PLAG1 Gene Fusion.
Alsugair Z, Perrot J, Descotes F, Lopez J, Champagnac A, Pissaloux D, Castain C, Onea M, Céruse P, Philouze P, Lépine C, Lanic MD, Laé M, Costes-Martineau V, Benzerdjeb N; and REFCOR Members. Alsugair Z, et al. Am J Surg Pathol. 2024 May 1;48(5):551-561. doi: 10.1097/PAS.0000000000002206. Epub 2024 Mar 18. Am J Surg Pathol. 2024. PMID: 38497430
Beneath HMGA2 alterations in pleomorphic adenomas: Pathological, immunohistochemical, and molecular insights.
Alsugair Z, Lépine C, Descotes F, Lanic MD, Pissaloux D, Tirode F, Lopez J, Céruse P, Philouze P, Fieux M, Wassef M, Baglin AC, Mihaela O, Castain C, Sudaka A, Uro-Coste E, Champagnac A, Costes-Martineau V, Laé M, Benzerdjeb N; REFCOR network*. Alsugair Z, et al. Hum Pathol. 2024 Oct;152:105633. doi: 10.1016/j.humpath.2024.105633. Epub 2024 Jul 30. Hum Pathol. 2024. PMID: 39089476 Free article.
Impact of facial nerve resection in parotid cancer abutting the facial nerve without preoperative paralysis: A multicentric propensity score-based analysis.
Chatelet F, Chevret S, Fakhry N, Even C, Malard O, de Monès E, Saroul N, Mouawad F, de Boutray M, Mauvais O, Vergez S, Evrard D, Righini C, Schultz P, Baudouin R, Poissonnet G, Atallah S, Haroun F, Morinière S, Evrard C, Philouze P, Paasche A, Lesnik M, Lelonge Y, Herman P, Verillaud B; REFCOR members. Chatelet F, et al. Eur J Surg Oncol. 2024 Oct 10:108746. doi: 10.1016/j.ejso.2024.108746. Online ahead of print. Eur J Surg Oncol. 2024. PMID: 39424524 Free article.
Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial.
Harrington KJ, Ferris RL, Gillison M, Tahara M, Argiris A, Fayette J, Schenker M, Bratland Å, Walker JWT, Grell P, Even C, Chung CH, Redman R, Coutte A, Salas S, Grant C, de Azevedo S, Soulières D, Hansen AR, Wei L, Khan TA, Miller-Moslin K, Roberts M, Haddad R. Harrington KJ, et al. Among authors: salas s. JAMA Oncol. 2023 Jun 1;9(6):779-789. doi: 10.1001/jamaoncol.2023.0147. JAMA Oncol. 2023. PMID: 37022706 Free PMC article.
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study.
Pant S, Schuler M, Iyer G, Witt O, Doi T, Qin S, Tabernero J, Reardon DA, Massard C, Minchom A, Lugowska I, Carranza O, Arnold D, Gutierrez M, Winter H, Stuyckens K, Crow L, Najmi S, Hammond C, Thomas S, Santiago-Walker A, Triantos S, Sweiti H, Loriot Y; RAGNAR Investigators. Pant S, et al. Lancet Oncol. 2023 Aug;24(8):925-935. doi: 10.1016/S1470-2045(23)00275-9. Lancet Oncol. 2023. PMID: 37541273 Free PMC article. Clinical Trial.
Phase Ib/II trial of tipapkinogene sovacivec, a therapeutic human papillomavirus16-vaccine, in combination with avelumab in patients with advanced human papillomavirus16-positive cancers.
Borcoman E, Lalanne A, Delord JP, Cassier PA, Rolland F, Salas S, Limacher JM, Capitain O, Lantz O, Ekwegbara C, Jeannot E, Cyrta J, Tran-Perennou C, Castel-Ajgal Z, Marret G, Piaggio E, Brandely M, Tavernaro A, Makhloufi H, Bendjama K, Le Tourneau C. Borcoman E, et al. Among authors: salas s. Eur J Cancer. 2023 Sep;191:112981. doi: 10.1016/j.ejca.2023.112981. Epub 2023 Jul 11. Eur J Cancer. 2023. PMID: 37506588 Clinical Trial.
374 results